Highly efficient asymmetric synthesis of sitagliptin.

A highly efficient synthesis of sitagliptin, a potent and selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM), has been developed. The key dehydrositagliptin intermediate 9 is prepared in three steps in one pot and directly isolated in 82% yield and >99.6 wt % purity. Highly enantioselective hydrogenation of dehydrositagliptin 9, with as low as 0.15 mol % of Rh(I)/(t)Bu JOSIPHOS, affords sitagliptin, which is finally isolated as its phosphate salt with nearly perfect optical and chemical purity. This environmentally friendly, 'green' synthesis significantly reduces the total waste generated per kilogram of sitagliptin produced in comparison with the first-generation route and completely eliminates aqueous waste streams. The efficiency of this cost-effective process, which has been implemented on manufacturing scale, results in up to 65% overall isolated yield.

[1]  A. Börner,et al.  Rhodium(I) catalyzed asymmetric hydrogenation of enamines , 2000 .

[2]  S. L. Gwaltney,et al.  Inhibitors of Dipeptidyl Peptidase 4 , 2005 .

[3]  Shane W. Krska,et al.  Highly efficient synthesis of beta-amino acid derivatives via asymmetric hydrogenation of unprotected enamines. , 2004, Journal of the American Chemical Society.

[4]  R. Reamer,et al.  The synthesis of 3-(1′-hydroxyethyl)-2-azetidinone-4-yl acetic acid via dianion chemistry - an important intermediate in thienamycin total synthesis , 1982 .

[5]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[6]  C. Starbuck,et al.  Identification of Ammonium Chloride as an Effective Promoter of the Asymmetric Hydrogenation of a β-Enamine Amide , 2006 .

[7]  K. Mohri,et al.  Meldrum's Acid in Organic Synthesis. VI. Synthesis of 2-Substituted Indoles from Acyl Meldrum's Acids and Phenylhydroxylamine via [3, 3] Sigmatropic Rearrangement , 1982 .

[8]  Edward J. J. Grabowski,et al.  First Generation Process for the Preparation of the DPP-IV Inhibitor Sitagliptin , 2005 .

[9]  Y. Hamada,et al.  Efficient total synthesis of didemnins A and B , 1989 .

[10]  S. Buchwald,et al.  ASYMMETRIC HYDROGENATION OF ENAMINES WITH A CHIRAL TITANOCENE CATALYST , 1994 .

[11]  N. Thornberry,et al.  Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin , 2007, Clinical pharmacology and therapeutics.

[12]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[13]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[14]  C. Fischer,et al.  Chiral β-Amino Acid Derivatives via Asymmetric Hydrogenation , 2003 .

[15]  D. Rich,et al.  Synthesis of the novel pi-(benzyloxymethyl)-protected histidine analogue of statine. Inhibition of penicillopepsin by pepstatin-derived peptides containing different statine side-chain derivatives. , 1989, Journal of medicinal chemistry.

[16]  U. Sørensen,et al.  A novel route to 5-substituted 3-isoxazolols. Cyclization of N, O-DiBoc beta-keto hydroxamic acids synthesized via acyl Meldrum's acids. , 2000, The Journal of organic chemistry.

[17]  Abdel-Magid Af,et al.  Chemical process synthesis of beta-amino acids and esters. , 1999 .

[18]  Jun‐An Ma.  Recent Developments in the Catalytic Asymmetric Synthesis of α‐ and β‐Amino Acids , 2003 .

[19]  George Zhou,et al.  Mechanistic Evidence for an α-Oxoketene Pathway in the Formation of β-Ketoamides/Esters via Meldrum's Acid Adducts , 2004 .

[20]  S. Campbell,et al.  Long-acting dihydropyridine calcium antagonists. 3. Synthesis and structure-activity relationships for a series of 2-[(heterocyclylmethoxy)methyl] derivatives. , 1989, Journal of medicinal chemistry.

[21]  N. Thornberry,et al.  Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes. , 2007 .

[22]  R. Houghton,et al.  A Modified Preparation of β-Keto Esters , 1982 .